Evidence map›Paper›PMID 40769972›Full record

ArticleNature communications2025

Plasmodium falciparum egress disrupts endothelial junctions and activates JAK-STAT signaling in a microvascular 3D blood-brain barrier model.

Livia Piatti, Alina Batzilla, Fumio Nakaki, Hannah Fleckenstein, François Korbmacher, Rory K M Long, Daniel Schraivogel, John A Hawkins, Tais Romero-Uruñuela, Borja López-Gutiérrez and 5 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. mBio · 2026
    Article
  5. bioRxiv : the preprint server for biology · 2026
    Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Febrile temperature enhancesbioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Livia Piatti *European Molecular Biology Laboratory (EMBL) Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0003-1571-3452
Alina Batzilla *European Molecular Biology Laboratory (EMBL) Barcelona, Barcelona, Spain.
Fumio NakakiEuropean Molecular Biology Laboratory (EMBL) Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0003-4332-7735
Hannah FleckensteinEuropean Molecular Biology Laboratory (EMBL) Barcelona, Barcelona, Spain.
François KorbmacherEuropean Molecular Biology Laboratory (EMBL) Barcelona, Barcelona, Spain.
Rory K M LongEuropean Molecular Biology Laboratory (EMBL) Barcelona, Barcelona, Spain.
Daniel SchraivogelEuropean Molecular Biology Laboratory (EMBL), Genome Biology Unit, Heidelberg, Germany.
John A HawkinsEuropean Molecular Biology Laboratory (EMBL), Genome Biology Unit, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-2943-9397
Tais Romero-UruñuelaEuropean Molecular Biology Laboratory (EMBL) Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0002-8009-3045
Borja López-GutiérrezEuropean Molecular Biology Laboratory (EMBL) Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0002-7159-5836
Silvia Sanz SenderEuropean Molecular Biology Laboratory (EMBL) Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0003-4334-3284
Yannick SchwabEuropean Molecular Biology Laboratory (EMBL), Cell Biology and Biophysics Unit, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-8027-1836
Lars M SteinmetzEuropean Molecular Biology Laboratory (EMBL), Genome Biology Unit, Heidelberg, Germany.
James SharpeEuropean Molecular Biology Laboratory (EMBL) Barcelona, Barcelona, Spain.
Maria BernabeuEuropean Molecular Biology Laboratory (EMBL) Barcelona, Barcelona, Spain. maria.bernabeu@embl.es.ORCID http://orcid.org/0000-0001-7212-6209

Funding

EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 948088European Molecular Biology Laboratory (EMBL Heidelberg) NA
6 · The paper itself

Abstract

Cerebral malaria is a severe neurovascular complication of Plasmodium falciparum infection, with high mortality rates even after treatment with effective antimalarials. Limitations in current experimental models have hindered our knowledge of the disease. We developed a 3D blood-brain barrier (BBB) model with enhanced barrier properties using primary brain endothelial cells, astrocytes, and pericytes. Exposure to parasite egress products increases microvascular permeability, likely due to transcriptional downregulation of junctional and vascular development genes in endothelial cells. In addition, it increases the expression of ferroptosis markers, antigen presentation and type I interferon genes and upregulates the JAK-STAT pathway across all BBB cell types. Incubation with cytoadherent schizont-stage P. falciparum-infected erythrocytes induces a similar, but highly localized transcriptional shift, along with inter-endothelial gaps at sites of parasite egress, leading to enhanced permeability. Treatment with the JAK-STAT inhibitor Ruxolitinib prevents the increase in permeability induced by P. falciparum egress products. These findings provide key insights into the parasite-mediated mechanisms driving brain microvascular pathogenesis in cerebral malaria and suggest potential avenues for adjunctive therapies.

Indexed as

Blood-Brain BarrierJanus KinasesMalaria, FalciparumPlasmodium falciparumSTAT Transcription FactorsAnimalsAstrocytesBrainCapillary PermeabilityEndothelial CellsErythrocytesHumansMalaria, CerebralMicrovesselsNitrilesPericytesJanus KinasesNitrilesPyrazolesPyrimidinesruxolitinibSTAT Transcription Factors

Identifiers

PMID40769972
PMCPMC12328663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.